SI3630112T1 - Kombinacija regorafeniba in nivolumaba za zdravljenje raka - Google Patents

Kombinacija regorafeniba in nivolumaba za zdravljenje raka

Info

Publication number
SI3630112T1
SI3630112T1 SI201831091T SI201831091T SI3630112T1 SI 3630112 T1 SI3630112 T1 SI 3630112T1 SI 201831091 T SI201831091 T SI 201831091T SI 201831091 T SI201831091 T SI 201831091T SI 3630112 T1 SI3630112 T1 SI 3630112T1
Authority
SI
Slovenia
Prior art keywords
regorafenib
nivolumab
combination
treating cancer
cancer
Prior art date
Application number
SI201831091T
Other languages
English (en)
Inventor
Sabine Hoff
Lars Rose
Dieter Zopf
Fabian Kiessling
Wiltrud Lederle
Dennis Doleschel
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of SI3630112T1 publication Critical patent/SI3630112T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201831091T 2017-06-02 2018-05-25 Kombinacija regorafeniba in nivolumaba za zdravljenje raka SI3630112T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17174169 2017-06-02
PCT/EP2018/063785 WO2018219807A1 (en) 2017-06-02 2018-05-25 Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
EP18725258.0A EP3630112B9 (en) 2017-06-02 2018-05-25 Combination of regorafenib and nivolumab for treating cancer

Publications (1)

Publication Number Publication Date
SI3630112T1 true SI3630112T1 (sl) 2024-06-28

Family

ID=58992733

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201831091T SI3630112T1 (sl) 2017-06-02 2018-05-25 Kombinacija regorafeniba in nivolumaba za zdravljenje raka

Country Status (21)

Country Link
US (4) US11951166B2 (sl)
EP (2) EP4342542A3 (sl)
JP (3) JP7303122B2 (sl)
KR (2) KR102673422B1 (sl)
CN (3) CN117899212A (sl)
AU (2) AU2018276273B2 (sl)
BR (1) BR112019025478A8 (sl)
CA (1) CA3065125A1 (sl)
DK (1) DK3630112T3 (sl)
ES (1) ES2978337T3 (sl)
FI (1) FI3630112T3 (sl)
HR (1) HRP20240551T1 (sl)
HU (1) HUE066487T2 (sl)
IL (1) IL270948A (sl)
LT (1) LT3630112T (sl)
MX (1) MX2023001721A (sl)
PL (1) PL3630112T3 (sl)
PT (1) PT3630112T (sl)
RS (1) RS65488B1 (sl)
SI (1) SI3630112T1 (sl)
WO (1) WO2018219807A1 (sl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018276273B2 (en) 2017-06-02 2023-12-21 Bayer Healthcare Llc Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
CN111001004A (zh) * 2019-10-08 2020-04-14 广州医科大学附属第二医院 一种治疗肝癌的药物组合及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004001834A1 (es) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
CA2628881A1 (en) 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl urea for treating diabetic neuropathy
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JO3479B1 (ar) * 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب
MY183969A (en) * 2012-09-25 2021-03-17 Bayer Pharma AG Combination of regorafenib and acetylsalicylic acid for treating cancer
JP5653489B1 (ja) 2013-07-24 2015-01-14 三菱エンジニアリングプラスチックス株式会社 薄肉光学部材用ポリカーボネート樹脂ペレット及びその製造方法
PT3498734T (pt) * 2014-02-04 2021-12-06 Pfizer Combinação de um antagonista da pd-1 e um inibidor do vegfr para tratamento de cancro
WO2015125652A1 (ja) 2014-02-21 2015-08-27 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤
CN106573060A (zh) * 2014-07-15 2017-04-19 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物
CN107072984B (zh) 2014-07-15 2021-10-01 约翰·霍普金斯大学 源自骨髓的抑制细胞的抑制和免疫检查点阻断
RU2731098C2 (ru) * 2014-08-19 2020-08-28 Нэшнл Юниверсити Корпорейшн Окаяма Юниверсити Способ улучшения функции иммунных клеток и оценки мультифункциональности иммунных клеток
EA201790737A1 (ru) 2014-10-03 2017-08-31 Новартис Аг Комбинированная терапия
KR20220054710A (ko) 2014-11-13 2022-05-03 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
WO2016173959A1 (en) * 2015-04-28 2016-11-03 Bayer Pharma Aktiengesellschaft Regorafenib for treating colorectal cancer
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
EP3463456A1 (en) 2016-06-03 2019-04-10 ImClone LLC Combination of ramucirumab and pembrolizumab for the treatment of certain cancers
US10251888B2 (en) 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
AU2018276273B2 (en) 2017-06-02 2023-12-21 Bayer Healthcare Llc Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
US10995149B2 (en) * 2017-06-05 2021-05-04 Janssen Biotech, Inc. Antibodies that specifically bind PD-1 and methods of use

Also Published As

Publication number Publication date
PL3630112T3 (pl) 2024-07-01
CN117899212A (zh) 2024-04-19
FI3630112T3 (fi) 2024-05-02
US20200155674A1 (en) 2020-05-21
JP2020521786A (ja) 2020-07-27
KR20200011971A (ko) 2020-02-04
RS65488B1 (sr) 2024-05-31
JP2024096905A (ja) 2024-07-17
WO2018219807A1 (en) 2018-12-06
JP2022169780A (ja) 2022-11-09
US11517622B2 (en) 2022-12-06
EP3630112B9 (en) 2024-06-26
HRP20240551T1 (hr) 2024-07-05
US20220133888A1 (en) 2022-05-05
BR112019025478A2 (pt) 2020-06-23
ES2978337T3 (es) 2024-09-10
PT3630112T (pt) 2024-04-23
HUE066487T2 (hu) 2024-08-28
JP7475402B2 (ja) 2024-04-26
CN110662540B (zh) 2024-01-26
JP7303122B2 (ja) 2023-07-04
CN110662540A (zh) 2020-01-07
CN117582495A (zh) 2024-02-23
EP4342542A2 (en) 2024-03-27
US20200188372A1 (en) 2020-06-18
RU2019143599A (ru) 2021-07-09
US20200179354A1 (en) 2020-06-11
EP3630112B1 (en) 2024-01-31
RU2019143599A3 (sl) 2021-09-10
KR102673422B1 (ko) 2024-06-07
IL270948A (en) 2020-01-30
CA3065125A1 (en) 2018-12-06
LT3630112T (lt) 2024-05-10
AU2018276273B2 (en) 2023-12-21
MX2023001721A (es) 2023-02-22
EP4342542A3 (en) 2024-06-05
BR112019025478A8 (pt) 2022-12-06
EP3630112A1 (en) 2020-04-08
DK3630112T3 (da) 2024-04-22
KR20240091188A (ko) 2024-06-21
AU2023282197A1 (en) 2024-01-04
US11951166B2 (en) 2024-04-09
AU2018276273A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
IL275663A (en) Cancer treatment methods
IL267247B (en) Compositions and methods for treating cancer
IL269150A (en) Preparations and methods for the treatment of cancer
IL258955A (en) Preparations and methods for the treatment of cancer
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
IL268814A (en) Preparations and methods for the treatment of cancer
IL276808A (en) Preparations and methods for the treatment of cancer
IL270511A (en) Combined treatments using niraparib and pembrolizumab for the treatment of cancer
ZA201900960B (en) Methods and compositions for the treatment of cancer
IL269157A (en) Preparations and methods for the treatment of cancer
IL274837A (en) Methods and preparations for the treatment of cancer
IL254842A0 (en) Therapeutic preparations and methods for use in cancer treatment
IL280587B (en) Fluorocitidine derivatives and their preparations for use in cancer treatment
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
IL276203A (en) Compounds and methods for treating cancer
IL267613A (en) Pancreatic cancer treatment
SG11202005163PA (en) Methods of treating cancer
IL255169A0 (en) Treatment combination of an anti-pogatactic factor and an immunotherapy factor and compounds for the treatment of cancer
IL272147A (en) Methods and preparations for the treatment of cancer
RS65488B1 (sr) Kombinacija regorafeniba i nivolumaba za lečenje karcinoma
IL272782A (en) Preparations and methods for the treatment of cancer
IL280262A (en) Compositions and methods for treating cancer
IL274748A (en) Improved cancer treatment
IL269123A (en) Methods of treating cancer
ZA201904626B (en) Cancer treatment method and composition